Johnson & Johnson Expects 2025 Sales Of $91B-$91.8B Versus Prior Guidance Of $90.9B–$91.7B And Consensus Of $90.62B

Benzinga
2025/04/15
($ in Billions, except EPS)April 2025January 2025

Adjusted Operational Sales1,2,5

Change vs. Prior Year / Mid-point

2.0% – 3.0% / 2.5%2.0% – 3.0% / 2.5%

Operational Sales2,5 / Mid-point

Change vs. Prior Year / Mid-point

$91.6B – $92.4B / $92.0B

3.3% – 4.3% / 3.8%

$90.9B – $91.7B / $91.3B

2.5% – 3.5% / 3.0%

Estimated Reported Sales3,5/ Mid-point

Change vs. Prior Year / Mid-point

$91.0B – $91.8B / $91.4B

2.6% – 3.6% / 3.1%

$89.2B – $90.0B / $89.6B

0.5% – 1.5% / 1.0%

Adjusted Operational EPS (Diluted)2,4 / Mid-point

Change vs. Prior Year / Mid-point

$10.50 – $10.70 / $10.60

5.2% – 7.2% / 6.2%

$10.75 – $10.95 / $10.85

7.7% – 9.7% / 8.7%

Adjusted EPS (Diluted)3,4 / Mid-point

Change vs. Prior Year / Mid-point

$10.50 – $10.70 / $10.60

5.2% – 7.2% / 6.2%

$10.50 – $10.70 / $10.60

5.2% – 7.2% / 6.2%

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10